mProX™ Human CD24 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD24 is a protein that has been studied in various applications. One study focused on the use of a humanized monoclonal antibody called IMM47 that targets CD24. This antibody showed exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction, making it a potential therapy for cancer immunotherapy. Another study investigated the immunological responses of Arsenicum album 30CH, a homeopathic remedy, as a prophylaxis for COVID-19. CD24 was one of the immunological markers assessed in this study. Additionally, CD24 was identified as one of the genes associated with anoikis in breast cancer, which is important for understanding the prognosis of the disease. Furthermore, CD24 was found to be involved in the CHI3L1/MAF/CTLA4 signaling pathway in triple-negative breast cancer, contributing to immune escape. Lastly, G-quadruplex structures formed by G-rich sequences in the regulatory regions of stem cell markers, including CD24, were characterized and could have implications for gene regulation. Overall, CD24 has been studied in the context of cancer immunotherapy, COVID-19 prophylaxis, breast cancer prognosis, immune escape, and gene regulation.